Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
Asti G, Curti N, Maggioni G, Carlini G, Lanino L, Campagna A, D'Amico S, Sauta E, Delleani M, Bonometti A, Lancellotti C, Rahal D, Ubezio M, Todisco G, Tentori C, Russo A, Crespi A, Figini G, Buizza A, Riva E, Zampini M, Brindisi M, Ficara F, Crisafulli L, Ventura D, Pinocchio N, Zazzetti E, Bicchieri M, Grondelli M, Forcina Barrero A, Savevski V, Santoro A, Santini V, Sole F, Platzbecker U, Fenaux P, Diez-Campelo M, Komrokji R, Haferlach T, Kordasti S, Di Tommaso L, Zeidan A, Loghavi S, Garcia-Manero G, Castellani G, Della Porta M. Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms. Blood 2024, 144: 3598-3598. DOI: 10.1182/blood-2024-206248.Peer-Reviewed Original ResearchLeukemia-free survivalMyeloid neoplasmsOverall survivalConcordance indexGenomic informationBone marrowPredictive of overall survivalMD Anderson Cancer CenterCell typesProportion of patientsHarrell's concordance indexSomatic gene mutationsMorphological featuresHumanitas Research HospitalGenomic dataMGG smearsPersonalized risk assessmentRUNX1 mutationsBM aspiratesClinically relevant informationClinical entityBiopsy dataMN patientsPrognostic assessmentWhole slide imagesImmune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.Peer-Reviewed Original ResearchAcute myeloid leukemiaAnti-PD-L1 antibody durvalumabOverall response rateMyelodysplastic syndromeComplete responseBM aspiratesMyeloid leukemiaInternational Working GroupBone marrowMyelodysplastic syndromes treated with azacitidineAcute myeloid leukemia ptsWild-type acute myeloid leukemiaSecondary acute myeloid leukemiaResponse criteriaAnti-PD-L1Immune checkpoint inhibitorsTreated with azacitidineOutcomes of patientsAny-cause deathGeneration of neoantigensVariant allele frequencySusceptible to treatmentMarrow CRAdverse cytogeneticsCheckpoint inhibitors